Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | BLM | P54132 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | ERN1 | O75460 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.31 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.31 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2557256 | 0.79 | LMNA (0.37) | MEN1LMNATHRBBLMKMT2A | |
| SCHEMBL4992978 | 0.75 | MEN1 (0.44) | MEN1LMNATHRBBLMKMT2A | |
| SCHEMBL4408085 | 0.73 | LMNA (0.42) | MEN1LMNATHRBBLMKMT2A | |
| SCHEMBL29519680 | 0.73 | CYP2B6 (0.43) | MEN1LMNATHRBBLMKMT2A | |
| SCHEMBL2557254 | 0.73 | CYP2B6 (0.43) | MEN1LMNATHRBBLMKMT2A | |
| SCHEMBL29385220 | 0.72 | PARP1 (0.53) | MEN1LMNATHRBBLMKMT2A | |
| SCHEMBL734868 | 0.72 | PARP1 (0.53) | MEN1LMNATHRBBLMKMT2A | |
| Hydrochloric Acid SCHEMBL30405223 | 0.71 | CYP2B6 (0.43) | MEN1LMNATHRBBLMKMT2A | |
| SCHEMBL2061341 | 0.71 | TDP1 (0.40) | MEN1KMT2ATDP1ERN1ALDH1A1 | |
| SCHEMBL3554338 | 0.70 | HTR7 (0.37) | LMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8236789-B2 | 1-adamantyl azetidin-2-one derivatives and drugs containing same | KOWA COMPANY, LTD. (JP) | 2012-08-07 | — | — | US | disclosed |
| EP-2322505-A1 | 1-ADAMANTYLAZETIDIN-2-ONE DERIVATIVE AND PHARMACEUTICAL PREPARATION COMPRISING SAME | Kowa Company, Ltd. (JP) | 2011-05-18 | — | — | EP | disclosed |
| US-20100075943-A1 | 1-ADAMANTYLAZETIDIN-2-ONE DERIVATIVES AND DRUGS CONTAINING SAME | KOWA COMPANY, LTD., (JP) | 2010-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100075943-A1 | 1-ADAMANTYLAZETIDIN-2-ONE DERIVATIVES AND DRUGS CONTAINING SAME | HSD11B1, HSD3B1, CYP46A1 | MEN1 311/4885LMNA 2573/4885THRB 1150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.